

23 February 2024

Kingworld Medicines Group Limited

Unit 613, 6th Floor
Goodluck Industrial Centre
808 Lai Chi Kok Road
Kowloon
Hong Kong

Dear Sirs/Madams,

**Re: Kingworld Medicines Group Limited (Stock Code: 1110)
(the “Company”, together with its subsidiaries, the “Group”)**

- Continuing connected transactions – Proposed Annual Caps for the three years ending 31 December 2026

We refer to the circular of the Company on the captioned matters dated 23 February 2024 (the “Circular”). Capitalised terms used herein shall have the same meaning as defined in the Circular unless otherwise stated.

In relation to our engagement as the independent financial adviser to advise the Independent Board Committee and the Independent Shareholders, we hereby give our consent and confirm that we have not withdrawn our consent to the issue of the Circular with the inclusion therein of our letter of advice (“**IFA Letter**”) and references to our name and logo in the form and context in which they are included.


We further confirm that, as at the Latest Practicable Date:

- (a) we did not have any shareholding in any member of the Group nor did we have any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for any securities in any member of the Group; and
- (b) we did not have any direct or indirect interest in any assets which have been, since 31 December 2022 (being the date to which the latest published audited accounts of the Group were made up), acquired or disposed of by or leased to any member of the Group, or are proposed to be acquired or disposed of by or leased to any member of the Group.

We also consent to a copy of this letter being made available for display on the websites of the Stock Exchange and the Company and be submitted to the Stock Exchange (if required).

Yours faithfully,

For and on behalf of
Vinco Financial Limited



Alister Chung
Managing Director